Kiladjian, Jean Jacques
Hôpital Saint-Louis,
France
2025 Rank: 50464
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 968 out of 166615 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 50464 | 39511 |
| Total Cites | 2649 | 3444 |
| H-index | 21 | 25 |
| Hm-index | 5 | 6 |
| Number of Single Authored Papers | 8 | 8 |
| Total Cites to Single Authored Papers | 2 | 2 |
| Number of Single+First Authored Papers | 39 | 39 |
| Total Cites to Single+First Authored Papers | 129 | 157 |
| Number of Single+First+Last Authored Papers | 76 | 76 |
| Total Cites to Single+First+Last Authored Papers | 272 | 330 |
| Composite Score | 2 | 3 |
| Number of Distinct Citing Papers | 1659 | 2042 |
| Ratio of Total Citations to Distinct Citing Papers | 1.60 | 1.69 |
| Self-Citation Percentage |
23.08%
|
|
Kiladjian, Jean Jacques
Université Paris Cité,
France
2022 Rank: 66206
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1623 out of 138599 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 66206 | 70307 |
| Total Cites | 905 | 1009 |
| H-index | 17 | 18 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 6 | 6 |
| Total Cites to Single Authored Papers | 7 | 7 |
| Number of Single+First Authored Papers | 28 | 28 |
| Total Cites to Single+First Authored Papers | 130 | 135 |
| Number of Single+First+Last Authored Papers | 44 | 44 |
| Total Cites to Single+First+Last Authored Papers | 183 | 195 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 482 | 522 |
| Ratio of Total Citations to Distinct Citing Papers | 1.88 | 1.93 |
| Self-Citation Percentage |
10.31%
|
|
Kiladjian, Jean Jacques
Université de Paris,
France
2021 Rank: 69555
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1572 out of 127911 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 69555 | 71894 |
| Total Cites | 1265 | 1527 |
| H-index | 20 | 21 |
| Hm-index | 5 | 5 |
| Number of Single Authored Papers | 6 | 6 |
| Total Cites to Single Authored Papers | 8 | 8 |
| Number of Single+First Authored Papers | 28 | 28 |
| Total Cites to Single+First Authored Papers | 203 | 215 |
| Number of Single+First+Last Authored Papers | 44 | 44 |
| Total Cites to Single+First+Last Authored Papers | 285 | 319 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 695 | 767 |
| Ratio of Total Citations to Distinct Citing Papers | 1.82 | 1.99 |
| Self-Citation Percentage |
17.16%
|
|
Kiladjian, Jean Jacques
Hôpital Saint-Louis,
France
2020 Rank: 80273
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1679 out of 108509 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 80273 | 77294 |
| Total Cites | 910 | 1108 |
| H-index | 16 | 18 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 6 | 6 |
| Total Cites to Single Authored Papers | 6 | 6 |
| Number of Single+First Authored Papers | 28 | 28 |
| Total Cites to Single+First Authored Papers | 118 | 126 |
| Number of Single+First+Last Authored Papers | 46 | 46 |
| Total Cites to Single+First+Last Authored Papers | 192 | 213 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 480 | 535 |
| Ratio of Total Citations to Distinct Citing Papers | 1.90 | 2.07 |
| Self-Citation Percentage |
17.87%
|
|
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.